QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
NYSEARCA:CNCR

Loncar Cancer Immunotherapy ETF - CNCR Stock Forecast, Price & News

$15.16
+0.20 (+1.34%)
(As of 02/2/2023 12:00 AM ET)
Add
Today's Range
$14.96
▼
$15.18
50-Day Range
$13.14
▼
$15.18
52-Week Range
$12.76
▼
$19.67
Volume
2,652 shs
Average Volume
2,725 shs
Market Capitalization
$22.74 million
P/E Ratio
N/A
Dividend Yield
0.00%
Price Target
N/A
Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Loncar Cancer Immunotherapy ETF and its competitors with MarketBeat's FREE daily newsletter.

Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Loncar Cancer Immunotherapy ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Exchange Traded Concepts
Fund NameLoncar Cancer Immunotherapy ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:CNCR
Inception Date10/13/2015
Fund ManagerDenise M. Krisko
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkLoncar Cancer Immunotherapy Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$22.79 million
Average Daily Volume$2,768.90
Discount/Premium-0.03%

ETF Expenses

Management Fee0.79%
Other Expenses0.00%
Total Expenses0.79%
Fee Waiver0.00%
Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorExchange Traded Concepts, LLC
CustodianU.S. Bank, N.A.
DistributorQuasar Distributors, LLC
Transfer AgentU.S. Bank, N.A.
Trustee
Lead Market MakerJane Street

Geographic Exposure of CNCR

Currency Exposure of CNCR

Sector Exposure of CNCR

Industry Exposure of CNCR














CNCR Stock - Frequently Asked Questions

How have CNCR shares performed in 2023?

Loncar Cancer Immunotherapy ETF's stock was trading at $13.73 at the beginning of 2023. Since then, CNCR shares have increased by 10.4% and is now trading at $15.16.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Loncar Cancer Immunotherapy ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Loncar Cancer Immunotherapy ETF investors own include Inovio Pharmaceuticals (INO), ARK Genomic Revolution Multi-Sector ETF (ARKG), VanEck Biotech ETF (BBH), Co-Diagnostics (CODX), Danaher (DHR), Fate Therapeutics (FATE), Gilead Sciences (GILD), GenMark Diagnostics (GNMK), iShares Genomics Immunology and Healthcare ETF (IDNA) and Novavax (NVAX).

What is Loncar Cancer Immunotherapy ETF's stock symbol?

Loncar Cancer Immunotherapy ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "CNCR."

How do I buy shares of Loncar Cancer Immunotherapy ETF?

Shares of CNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Loncar Cancer Immunotherapy ETF's stock price today?

One share of CNCR stock can currently be purchased for approximately $15.16.

How much money does Loncar Cancer Immunotherapy ETF make?

Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR) has a market capitalization of $22.74 million.

This page (NYSEARCA:CNCR) was last updated on 2/3/2023 by MarketBeat.com Staff